Hassan Refaat, Gudiwala Viral, Dawn Pretty, Jeynes Louise
School of Clinical Medicine, University of Cambridge, Cambridge, GBR.
Pain Medicine, West Suffolk Hospital, Bury St Edmunds, GBR.
Cureus. 2023 Feb 13;15(2):e34930. doi: 10.7759/cureus.34930. eCollection 2023 Feb.
Background Migraine is a common complaint worldwide, spanning all ages, but is not so well investigated in children and adolescents. Pediatric migraines incur significant health and social consequences with the most incisive effects seen in school performance, physical health, and mental well-being, making early effective management of pediatric migraine desirable. However, unlike adult migraine, the treatment for pediatric migraine has not been well established, which is especially true for the treatment of medically refractory migraine in children. Methodology We conducted a retrospective study to assess the feasibility of greater occipital nerve (GON) blocks as a therapeutic option for medically refractory migraine in children. We recruited subjects under 18 years old with a severe medically refractory headache that was affecting day-to-day life and who consented to receive a GON block. GON block effectivity was assessed through follow-up consultations and a post-procedural questionnaire. Results Six subjects received a first-time GON block for medically refractory migraine (mean age = 12 years and three months old, age range = 10 to 15 years old, three out of six subjects were female). We found that GON block was effective in all six patients for treatment of medically refractory migraine as assessed through follow-up consultations and a questionnaire sent out six weeks post-intervention. GON block was generally tolerable with only one patient reporting side effects (migraine flare-up for three days) post-intervention. Repeat injection was performed in four out of six patients, all of whom reported a repeat benefit. Conclusions We conclude that GON block is a feasible therapeutic option for the management of medically refractory migraine in children.
偏头痛是全球常见的病症,涵盖所有年龄段,但在儿童和青少年中的研究尚不充分。儿童偏头痛会引发重大的健康和社会后果,在学业表现、身体健康和心理健康方面影响最为显著,因此早期有效管理儿童偏头痛很有必要。然而,与成人偏头痛不同,儿童偏头痛的治疗方法尚未明确确立,对于儿童药物难治性偏头痛的治疗尤其如此。
我们进行了一项回顾性研究,以评估枕大神经(GON)阻滞作为儿童药物难治性偏头痛治疗选择的可行性。我们招募了18岁以下患有严重药物难治性头痛且影响日常生活并同意接受GON阻滞的受试者。通过随访咨询和术后问卷评估GON阻滞的有效性。
六名受试者因药物难治性偏头痛首次接受GON阻滞(平均年龄 = 12岁零三个月,年龄范围 = 10至15岁,六名受试者中有三名女性)。通过随访咨询和干预六周后发出的问卷评估,我们发现GON阻滞对所有六名患者治疗药物难治性偏头痛均有效。GON阻滞一般耐受性良好,只有一名患者在干预后报告有副作用(偏头痛发作三天)。六名患者中有四名进行了重复注射,所有这些患者均报告有重复疗效。
我们得出结论,GON阻滞是治疗儿童药物难治性偏头痛的一种可行治疗选择。